期刊
JHEP REPORTS
卷 2, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jhepr.2019.12.001
关键词
NSBBs; ACLF; ascites; cirrhosis; spontaneous bacterial peritonitis; portal hypertension; varices
Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in the setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in preventing initial variceal bleeding and subsequent rebleeding. Recent evidence indicates that NSBBs could prevent liver decompensation in patients with compensated cirrhosis. Despite solid data favouring NSBB use in cirrhosis, some studies have highlighted relevant safety issues in patients with end-stage liver disease, particularly with refractory ascites and infection. This review summarises the evidence supporting current recommendations and restrictions of NSBB use in patients with cirrhosis. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据